Original site: www.cdc.gov/mmwr/preview/mmwrhtml/mm5302a6.htm | RestoredCDC.org is an independent project, not affiliated with CDC or any federal entity. Visit CDC.gov for free official information. Due to archival on January 6, 2025, recent outbreak data is unavailable. Videos are not restored. Access data.restoredcdc.org for restored data. Use of this site implies acceptance of this disclaimer.

[More]
About Us Report Bug

RestoredCDC.org Comparison

Comparison timestamp: 2025-05-02 00:31:44 UTC
RestoredCDC URL: http://restoredcdc.org/www.cdc.gov/mmwr/preview/mmwrhtml/mm5302a6.htm
Live cdc.gov URL ↗: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5302a6.htm
Removed: Line removed from cdc.gov. Specific word removals are highlighted.
Added: Line added to cdc.gov. Specific word additions are highlighted.
Injected: Line or disclaimer added by RestoredCDC.org.
Unchanged: Line unchanged.
Original site: www.cdc.gov/mmwr/preview/mmwrhtml/mm5302a6.htm | RestoredCDC.org is an independent project, not affiliated with CDC or any federal entity. Visit CDC.gov for free official information. Due to archival on January 6, 2025, recent outbreak data is unavailable. Videos are not restored. Access data.restoredcdc.org for restored data. Use of this site implies acceptance of this disclaimer.
[More]
About Us Report Bug Compare Content
Weekly
January 23, 2004 / 53(02);37
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Notice to Readers: Updated Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors
Guidelines for managing the pharmacologic interactions that can result when patients receive protease inhibitors (PIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) for treatment of human immunodeficiency virus (HIV) infection together with rifamycins for the treatment of tuberculosis have been published previously (1,2). New guidelines regarding interactions among these agents, with recommendations for their use from CDC and partners, are available at http://www.cdc.gov/nchstp/tb/tb_hiv_drugs/toc.htm. Information includes initial recommendations for the new PIs lopinavir/ritonavir, atazanavir, and fosamprenavir, and updated recommendations for other dual PI regimens and NNRTIs. The new recommendations expand the use of rifampin with these antiretroviral drugs, which is critical in regions where rifabutin is unavailable. Periodic updates will be posted to the website to provide clinicians with the latest information.
References
1. CDC. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 1998;47(No. RR-20).
2. CDC. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR 2000;49:185--9.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
Disclaimer All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.
Page converted: 1/22/2004
HOME | ABOUT MMWR | MMWR SEARCH | DOWNLOADS | RSS | CONTACT
POLICY | DISCLAIMER | ACCESSIBILITY
Department of Health
Morbidity and Mortality Weekly Report and Human Services
Centers for Disease Control and Prevention
1600 Clifton Rd, MailStop E-90, Atlanta, GA 30333, U.S.A
This page last reviewed 1/22/2004
Note: Comparison ignores leading/trailing whitespace and certain script/tracking codes. Word-level highlighting (optional above) only applies to changed lines.